Some Aspects of the Renin-Angiotensin-System in Hemodialysis Patients

被引:20
|
作者
Malik, Umar [1 ]
Raizada, Veena [1 ]
机构
[1] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA
来源
KIDNEY & BLOOD PRESSURE RESEARCH | 2015年 / 40卷 / 06期
关键词
RAS; Renin-angiotensin system; Angiotensin II; ACE; ACE2; Hemodialysis; Hypertension; ESRD; Cardiovascular disease; CORONARY-ARTERY-DISEASE; CHRONIC KIDNEY-DISEASE; ENZYME; ACTIVITY; CONVERTING-ENZYME; HEART-FAILURE; CARDIOVASCULAR-DISEASE; DIALYSIS PATIENTS; ENDOTHELIAL FUNCTION; COLLECTING DUCT; BLOOD-PRESSURE;
D O I
10.1159/000368537
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Understanding of the renin-angiotensin system (RAS) has changed remarkably over the past decade. Renin, angiotensin converting enzyme (ACE), angiotensin II (Ang II), and Ang II receptors are the main components of the RAS. Recent studies identified the ACE2/Ang 1-7/Mas receptor axis, which counter-regulates the classical RAS. Many studies have examined the effects of the RAS on the progression of cardiovascular disease and chronic kidney disease (CKD). In addition, many studies have documented increased levels of ACE in hemodialysis (HD) patients, raising concerns about the negative effects of RAS activation on the progression of renal disease. Elevated ACE increases the level of Ang II, leading to vasoconstriction and cell proliferation. Ang II stimulation of the sympathetic system leads to renal and cardiovascular complications that are secondary to uncontrolled hypertension. This review provides an overview of the RAS, evaluates new research on the role of ACE2 in dialysis, and reviews the evidence for potentially better treatments for patients undergoing HD. Further understanding of the role of ACE and ACE2 in HD patients may aid the development of targeted therapies that slow the progression of CKD and cardiovascular disease. (C) 2015 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:614 / 622
页数:9
相关论文
共 50 条
  • [1] MOLECULAR EFFECTS OF RENIN-ANGIOTENSIN-SYSTEM BLOCKADE IN HEMODIALYSIS PATIENTS
    Antlanger, Marlies
    Kovarik, Johannes J.
    Domenig, Oliver
    Kaltenecker, Christopher
    Hecking, Manfred
    Haidinger, Michael
    Werzowa, Johannes
    Kopecky, Chantal
    Heinzl, Harald
    Poglitsch, Marko
    Saeemann, Marcus D.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 93 - 93
  • [2] The renin-angiotensin system [Das Renin-Angiotensin-System]
    Hilgers Dr. K.F.
    Der Nephrologe, 2009, 4 (4): : 351 - 361
  • [3] Inflammation and the renin-angiotensin-system
    Kintscher, Ulrich
    INFLAMMATION RESEARCH, 2007, 56 : S328 - S328
  • [4] Das Renin-Angiotensin-System
    Der Urologe, 2009, 48 : 925 - 935
  • [5] RENIN-ANGIOTENSIN-SYSTEM IN PATIENTS WITH DIABETES-MELLITUS
    MANN, J
    RITZ, E
    KLINISCHE WOCHENSCHRIFT, 1988, 66 (18): : 883 - 891
  • [6] Lymphatic vessels and the renin-angiotensin-system
    Bertoldi, Giovanni
    Caputo, Ilaria
    Calo, Lorenzo
    Rossitto, Giacomo
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2023, 325 (04): : H837 - H855
  • [7] COPIOUS DRINKING AND RENIN-ANGIOTENSIN-SYSTEM
    HERTTING, G
    MEYER, DK
    JAPANESE JOURNAL OF PHARMACOLOGY, 1976, 26 : P2 - P2
  • [8] IMMUNOHISTOCHEMISTRY OF THE RENIN-ANGIOTENSIN-SYSTEM IN THE KIDNEY
    TAUGNER, R
    BUHRLE, CP
    GANTEN, D
    HACKENTHAL, E
    HARDEGG, C
    HARDEGG, G
    NOBILING, R
    CLINICAL AND EXPERIMENTAL HYPERTENSION PART A-THEORY AND PRACTICE, 1983, 5 (7-8) : 1163 - 1177
  • [9] Pathophysiology of the renin-angiotensin-system in atrial fibrillation
    Heusch, G
    Schulz, R
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2006, 131 (15) : 817 - 820
  • [10] Renin-angiotensin-system blockade in the prevention of diabetes
    Ostergren, Jan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 : S13 - S21